Clinician participation in CADTH's pan-Canadian Oncology Drug Review: contribution and impact on cancer drug funding recommendations

被引：1

作者：

Trudeau, M. ^{[2
]}

Hoskins, P. ^{[3
]}

Reiman, T. ^{[4
,5
,6
]}

Chambers, A. ^{[1
]}

Mai, H. ^{[1
]}

Wheatley-Price, P. ^{[7
,8
]}

机构：

[1] Pan Canadian Oncol Drug Review, Canadian Agcy Drugs & Technol Hlth, 154 Univ Ave,Suite 300, Toronto, ON M5H 3Y9, Canada

[2] Sunnybrook Odette Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[3] BC Canc Agcy, Med Oncol, Vancouver, BC, Canada

[4] St Johns Hosp, Dept Oncol, St John, NB, Canada

[5] Dalhousie Univ, Dept Med, Halifax, NS, Canada

[6] Univ New Brunswick, Dept Biol, St John, NB, Canada

[7] Ottawa Hosp, Dept Med, Ottawa, ON, Canada

[8] Ottawa Hosp Res Inst, Ottawa, ON, Canada

来源：

关键词：

D O I：

10.3747/co.24.3644

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：71 / 74

页数：4

共 6 条

[1]

Canadian Agency for Drugs and Technologies in Health (cadth), 2016, PCODR EXP REV COMM D

[2]

Canadian Agency for Drugs and Technologies in Health (cadth), 2017, PAN CAN ONC DRUG REV

[3]

Canadian Agency for Drugs and Technologies in Health (cadth), 2017, FIND A REV PCODR

[4]

Canadian Agency for Drugs and Technologies in Health (cadth), 2017, PAN

[5]

Canadian Agency for Drugs and Technologies in Health (cadth), 2016, NEW PIL IN INCR OPP

[6]

The Council of the Federation, 2016, PAN CAN PHARM ALL